2269:HKG
WuXi Biologics (Cayman) Inc
49,60Â HKD
arrow_downward
-0,28%(-0,14) 1G
15 ott, 11:29:03 GMT+8 · HKD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per 2269 in corso…
Apertura
49,12Â HKD
Massimo
50,30Â HKD
Minimo
49,12Â HKD
Cap. mercato
204,11Â Mld
Vol. medio
29,86Â Mln
Volume
16,74Â Mln
Rapporto P/E
35,48
Max 52 sett.
58,00Â HKD
Min 52 sett.
28,48Â HKD
Utili per azione
1,40Â HKD
Azioni in circolazione
1,23Â Mld
N. di dipendenti
15K
Apertura
49,12Â HKD
Massimo
50,30Â HKD
Minimo
49,12Â HKD
Cap. mercato
204,11Â Mld
Vol. medio
29,86Â Mln
Volume
16,74Â Mln
Rapporto P/E
35,48
Max 52 sett.
58,00Â HKD
Min 52 sett.
28,48Â HKD
Utili per azione
1,40Â HKD
Azioni in circolazione
1,23Â Mld
N. di dipendenti
15K
Articoli giornalistici
Da fonti web e partner giornalistici
MarketScreener Italia
·
7 ore fa
Il Nasdaq chiude nettamente in calo, mentre i dati sull'inflazione alimentano i timori di nuovi rialzi dei tassi
Yahoo Finanza
·
2 ore fa
L’S&P 500 entra nella sua finestra stagionale più forte
Agenzia Nova
·
13 ore fa
Usa: Wall Street apre in calo dopo i dati sull’inflazione ed il rialzo dei rendimenti
MarketScreener Italia
·
6 ore fa
Nasdaq e S&P 500 in calo per la terza seduta consecutiva dopo i dati sull'inflazione al consumo
Profilo
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Informazioni su WuXi Biologics (Cayman) Inc